ALFA Finder| Revenue growth | Directionally up YoY; no growth % disclosed by management. |
|---|---|
| Margins | Contraction: pharma 4.6% vs ~13.7% year ago; crop EBIT negative. |
| Order book | Single multi-year CDMO contract; no order book value stated. |
| Demand visibility | Legacy demand recovering; crop destocking over; CDMO demand deferred H2. |
| Management confidence | Defensive on USFDA, hedged 'hopeful'; 'significantly better H2' unquantified. |
Growth
Revenue, volume and EBITDA grew YoY, but no growth % was disclosed. Pharma Q2 margin 4.6% vs ~13.7% a year earlier (analyst figure).
Outlook
Reiterated mid-teens revenue growth for the full year. H2 'significantly better' is unquantified. USFDA clearance could add ~₹150 Cr revenue.
Risks
Raw material costs up over 100%, with pass-through lagging. USFDA reinspection timing unconfirmed. ~₹20 Cr/yr remediation cost.
Last quarter's promises, checked
Partly delivered
- FY27 revenue +14–16% → H1 ₹837 Cr; growth % and FY26 base undisclosed (= PARTIAL)
- FY27 EBITDA +25–30% → H1 ₹82 Cr; growth % undisclosed (= PARTIAL)
- Q2 'substantial' YoY revenue/EBITDA growth → up, magnitude undisclosed (= PARTIAL)
Missed
- Legacy pharma YoY margin recovery → Q2 pharma 4.6% vs ~13.7% yr ago (= MISS)
- Crop Q2 better than Q1 → implied Q2 ₹156 Cr (H1 326 − Q1 170) vs Q1 ₹170 Cr (= MISS)
- Raw-material prices down by end-Q2 → RM costs still up >100%, pass-through lagging (= MISS)
Earnings Call Transcript filed with BSE, NSE: HIKAL. Summary written with AI assistance from the document.
Hikal Ltd: key numbers
- Share price
- ₹219.52
- Market cap
- ₹2,707 Cr
- Revenue (annual)
- ₹1,713 Cr
- Net profit (annual)
- ₹-48.80 Cr
- P/E (TTM)
- -541.3×Sector 43.0×
- Promoter holding
- 68.85%+0.00% QoQ
- FII holding
- 1.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hikal Ltd
All →Hikal Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹434 Cr (+36% YoY), EBITDA ₹45 Cr at 10.3% margin, PAT loss narrowed to ₹(6) Cr. Pharma led recovery; Crop Protection margins pressured.
Hikal Results Update
Hikal Ltd reported Q2 FY27 revenue of ₹434 Crore and an EBITDA of ₹45 Crore. The company also announced the commencement of commercial production for Personal Care at its Panoli facility.
- Value
- ₹434.0 Cr
Hikal Q2 FY27 Results: Net Loss of ₹6.1 Cr, Loss Narrows
Hikal Ltd reported revenue from operations of ₹434.2 Cr (+36.3% YoY) and a net loss of ₹6.1 Cr for Q2 FY27.
- Key figure
- Net loss ₹6.1 Cr
Hikal Bags New Order from Europe-based global agrochemical company
Hikal signed a multi-year CDMO contract with a Europe-based global agrochemical company for a specialised product. Commercial launch is expected towards the end of FY 2026-27.
- From
- Europe-based global agrochemical company (unnamed)
- Execution
- Multi-year
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Hikal Other Announcement
Hikal Ltd filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing reports routine ownership data with no new transaction.